GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: GSK839 is a selective inhibitor of Mycobacterium tuberculosis tryptophan synthase (TrpAB) that is in preclinical evaluation for the treatment of tuberculosis. It is one of the compounds claimed by GlaxoSmithKline in patent WO2019034729A1 [1].
|
|
Bioactivity Comments |
The MIC for in vitro antimycobacterial activity against M. tuberculosis H37Rv is 0.07 μg/ml [1-2]. |